Keybanc analyst Kenneth Zener downgrades Sherwin-Williams (NYSE:SHW) from Overweight to Sector Weight.
Allogene Therapeutics Q4 EPS $(0.66) Beats $(0.70) Estimate, Sales $47.00K Miss $60.00K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.70) by 5.71 percent. This is a 22.22 percent decrease over losses of $(0.54) per share